This suggests that SYK inhibition may be an effective treatment in more inflammatory forms of glomerulonephritis, such as ANCA-associated glomerulonephritis, and our findings in this preclinical model suggest that this approach should be tested in clinical studies of AAV. This evidence concerns the gene SYK and anti-neutrophil cytoplasmic antibody-associated vasculitis.